Literature DB >> 33541284

Long non-coding RNA H19 expression and functional polymorphism rs217727 are linked to increased ischemic stroke risk.

Mohadese Rezaei1, Mohammad Javad Mokhtari2, Mahnaz Bayat3, Anahid Safari4, Mehdi Dianatpuor4, Reza Tabrizi5, Tahereh Asadabadi1, Afshin Borhani-Haghighi3.   

Abstract

BACKGROUND: Efforts to identify potential biomarkers for the diagnosis of ischemic stroke (IS) are valuable. The H19 gene plays a functional role in increasing the prevalence of IS risk factors. We evaluated the correlation between H19 rs217727 polymorphism and the expression level of H19 lncRNA with susceptibility to IS among the Iranian population.
METHODS: Blood samples were collected from IS patients (n = 114) and controls (n = 114). We concentrated on the expression pattern of H19 at different time points (i.e., 0-24, 24-48, and 48-72 h after stroke). The tetra-amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) method was applied for DNA genotyping. We used the quantitative real-time PCR to evaluate H19 expression levels. We used the receiver operating characteristic (ROC) curve to evaluate the diagnosis and prognosis of IS.
RESULTS: The rs217727polymorphism of H19 was related with IS susceptibility in the co-dominant (OR = 2.92, 95% CI = 0.91-10.92, P = 0.04) and recessive models (OR = 2.80, 95% CI = 0.96-8.15, P = 0.04). H19 expression was significantly upregulated in IS and remained high for 72 h after stroke. ROC curves showed that H19 expression within the first 24 h from stroke onset might serve as a biomarker for the early diagnosis of IS with 79.49% sensitivity and 80.00% specificity. H19 expression in small vessel occlusion (SVO) and large-artery atherosclerosis (LAA) patients were 3.74 and 3.34 times higher than the undetermined (UD) subtype, respectively [OR = 3.74 95% CL (1.14-12.27) P = 0.030 and OR = 3.34 95% CL (1.13-9.85) P = 0.029].
CONCLUSION: The rs217727 polymorphism of the H19 is correlated with IS susceptibility, and H19 expression levels were higher in SVO and LAA patients. The upregulation of H19 may be considered as a diagnostic biomarker in IS among the Iranian population, but it cannot serve as a useful prognostic marker.

Entities:  

Keywords:  Biomarker; Diagnosis; Gene polymorphism; Ischemic stroke; Long non coding- RNA

Mesh:

Substances:

Year:  2021        PMID: 33541284      PMCID: PMC7860182          DOI: 10.1186/s12883-021-02081-3

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  39 in total

1.  Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization.

Authors:  Jue Wang; Haiping Zhao; Zhibin Fan; Guangwen Li; Qingfeng Ma; Zhen Tao; Rongliang Wang; Juan Feng; Yumin Luo
Journal:  Stroke       Date:  2017-06-19       Impact factor: 7.914

Review 2.  Long non-coding RNAs: insights into functions.

Authors:  Tim R Mercer; Marcel E Dinger; John S Mattick
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

3.  Targeting autophagy to prevent neonatal stroke damage.

Authors:  Julien Puyal; Peter G H Clarke
Journal:  Autophagy       Date:  2009-10-05       Impact factor: 16.016

Review 4.  SNPs: impact on gene function and phenotype.

Authors:  Barkur S Shastry
Journal:  Methods Mol Biol       Date:  2009

5.  Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer.

Authors:  Safa Abdollahzadeh; Saeid Ghorbian
Journal:  J Clin Lab Anal       Date:  2018-11-28       Impact factor: 2.352

Review 6.  Roles of long noncoding RNAs in gastric cancer and their clinical applications.

Authors:  Weiliang Sun; Yunben Yang; Chunjing Xu; Yi Xie; Junming Guo
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-31       Impact factor: 4.553

7.  Regulation of endoplasmic reticulum stress in rat cortex by p62/ZIP through the Keap1-Nrf2-ARE signalling pathway after transient focal cerebral ischaemia.

Authors:  Weiwei Wang; Jinsong Kang; Hongyan Li; Jing Su; Jiang Wu; Ye Xu; Huimei Yu; Xiyan Xiang; Haowei Yi; Yuxiong Lu; Liankun Sun
Journal:  Brain Inj       Date:  2013-06-19       Impact factor: 2.311

8.  Blocking lncRNA H19-miR-19a-Id2 axis attenuates hypoxia/ischemia induced neuronal injury.

Authors:  Zhipeng Xiao; Yongming Qiu; Yingying Lin; Rogelio Medina; Sophie Zhuang; Jared S Rosenblum; Jing Cui; Zezhi Li; Xiaohua Zhang; Liemei Guo
Journal:  Aging (Albany NY)       Date:  2019-06-05       Impact factor: 5.682

Review 9.  The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma.

Authors:  Lysann Tietze; Sonja M Kessler
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

Review 10.  Biomarkers for stroke.

Authors:  Suk Jae Kim; Gyeong Joon Moon; Oh Young Bang
Journal:  J Stroke       Date:  2013-01-31       Impact factor: 6.967

View more
  5 in total

Review 1.  Epigenetic mechanisms and potential therapeutic targets in stroke.

Authors:  Kahlilia C Morris-Blanco; Anil K Chokkalla; Vijay Arruri; Soomin Jeong; Samantha M Probelsky; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2022-07-19       Impact factor: 6.960

Review 2.  Role of autophagy and transcriptome regulation in acute brain injury.

Authors:  Vijay Arruri; Raghu Vemuganti
Journal:  Exp Neurol       Date:  2022-03-05       Impact factor: 5.620

3.  Effects and early diagnostic value of lncRNA H19 on sepsis-induced acute lung injury.

Authors:  You Zhou; Liqun Sun; Mingyu Zhu; He Cheng
Journal:  Exp Ther Med       Date:  2022-02-14       Impact factor: 2.447

Review 4.  The multifaceted actions of the lncRNA H19 in cardiovascular biology and diseases.

Authors:  Denise Busscher; Reinier A Boon; Rio P Juni
Journal:  Clin Sci (Lond)       Date:  2022-08-12       Impact factor: 6.876

5.  Network Pharmacology and Bioinformatics Methods Reveal the Mechanism of Berberine in the Treatment of Ischaemic Stroke.

Authors:  Ke Song; Yikun Sun; Haoqi Liu; Yuanyuan Li; Na An; Liqin Wang; Hanlai Zhang; Fan Yang; Yanwei Xing; Yonghong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.